NCT03529422 · OUTCOME

Overall Survial in Patients With Intermediate-risk HNSCC Treated With Adjuvant Durvalumab With Radiotherapy PD-L1 Expression With Disease Free Survival

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN · Source last updated 2026-06-23

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 5 years

What was measured

To estimate median OS in patients with intermediate-risk HNSCC treated with adjuvant durvalumab with radiotherapy.-To correlate PD-L1 expression with disease free survival

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: To estimate median OS in patients with intermediate-risk HNSCC treated with adjuvant durvalumab with radiotherapy.-To correlate PD-L1 expression with disease free survival
reporting Status: NOT_POSTED
time Frame: 5 years
title: Overall Survial in Patients With Intermediate-risk HNSCC Treated With Adjuvant Durvalumab With Radiotherapy PD-L1 Expression With Disease Free Survival
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice